Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Cue Biopharma has a market cap or net worth of $47.36M. The enterprise value is $67.34M.

Cue Biopharma has 61.82M shares outstanding. The number of shares has decreased by -2.65% in one year.

Cue Biopharma’s return on equity (ROE) is -1.37 and return on invested capital (ROIC) is -100.71%.

The current PE Ratio of Cue Biopharma is -2.38. Cue Biopharma’s PEG ratio is 0.10.

In the last 12 months, Cue Biopharma had revenue of $9.53M and earned -$44.61M in profits. Earnings per share was -$0.90.

In the last 12 months, operating cash flow was -$38.26M and capital expenditures -$64.00K, giving a free cash flow of -$38.32M billion.

Cue Biopharma pays an annual dividend of , resulting in a dividend yield of

Cue Biopharma upcoming earnings date is May 13, 2025, TBA.

Cue Biopharma as a current ratio of 3.01, with Debt / Equity ratio of 0.40

In the past 12 months, Cue Biopharma has paid $1.61M in taxes.

Cue Biopharma EV to EBITDA ratio is -1.89, with an EV/FCF ratio of -2.18.

Cue Biopharma has $32.42M in cash and marketable securities with $9.51M in debt, giving a net cash position of -$22.91M billion.

Gross margin is -593.93%, with operating margin of -949.89%, and net profit margin of -924.10%.

The average price target for Cue Biopharma is $2.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy